Latest Insmed News & Updates

See the latest news and media coverage for Insmed. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Insmed

Biopharmaceutical company developing therapies for serious diseases

insmed.com
Headquarters
Bridgewater Township, United States
Company type
Public company
Number of employees
1,600–5,000

Last updated

Latest news about Insmed

In short: Insmed achieved major regulatory milestones with Brinsupri and Arikayce while experiencing clinical setbacks in its brensocatib skin program.

Company announcements

  • Insmed

    Insmed reports Q1 2026 financial results

    Total revenues reach $306M with BRINSUPRI at $207.9M and ARIKAYCE at $98.1M. Reiterates 2026 guidance. ENCORE study meets endpoints; PALM-PAH initiated.

  • Insmed

    Insmed presents respiratory portfolio data at ATS 2026

    Includes late-breaking ARIKAYCE Phase 3b ENCORE results, BRINSUPRI analysis, TPIP pharmacokinetics, and grants ATS for bronchiectasis diagnosis.

  • Insmed

    Insmed announces CEDAR study fails endpoints

    Insmed discontinues brensocatib HS program. Safety consistent with prior studies, no new signals. Data shows placebo outperformed treatment arms.

  • Insmed

    Insmed announces positive topline results from Phase 3b ENCORE study

    The study met primary and secondary endpoints, showing improvements in respiratory symptoms and culture conversion rates for ARIKAYCE in MAC lung disease patients. Insmed plans sNDA filing in 2026.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about Insmed

Track Insmed and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.